Event has already taken place!
Reimagining Career Possibilities: Biotech Start-ups
Event Details
A well-known saying, ‘I would take the road less travelled’ suits well to our speaker Assistant Professor Dr Minh Le, who has established her career from a biomedical PhD to
Event Details
A well-known saying, ‘I would take the road less travelled’ suits well to our speaker Assistant Professor Dr Minh Le, who has established her career from a biomedical PhD to a co-founder of Carmine Therapeutics, a start-up company based on red blood cell EVs in Singapore and Boston. She will share the key decisions made and deep dives into the critical ‘breaks’ and ‘mistakes’ made and lessons drawn in her career leading to the birth of Carmine therapeutics. It is a great opportunity for everyone who is keen to find out how it is like to start a biotech startup, and how to transition into it!
Please register by clicking on the following link:
https://us02web.zoom.us/webinar/register/WN_7nzVZyChQzWTe4P78aF78Q
About the Speaker:
Dr. Le graduated from the National University of Singapore in 2005 with a bachelor’s degree in Life Sciences. She further received a Ph.D. degree in Computational and Systems Biology from the Singapore-Massachusetts Institute of Technology (MIT) Alliance under the guidance of Prof. Bing Lim at the Genome Institute of Singapore and Prof. Harvey Lodish at the Whitehead Institute for Biomedical Research. From 2010 to 2015, she took a postdoctoral training under Prof. Judy Lieberman at Boston Children’s Hospital and Harvard Medical School in the USA. From 2015 to 2019, she worked as an Assistant Professor at the Department of Biomedical Sciences at City University of Hong Kong (CityU). She became a tenure-tracked Assistant Professor at Department of Pharmacology, National University of Singapore, in 2019.
Dr. Le is well recognized for her contributions to the field of microRNAs (miRNAs), extracellular vesicles (EVs) and cancer biology. She was the first to identify a miRNA that regulates p53, an important tumor suppressor gene. This miRNA, miR-125b, was subsequently found to be a potent oncogenic miRNA in leukemia and many solid tumors. Dr. Le characterized the anti-apoptotic functions of miR-125b in zebrafish embryos and mammalian cells. She demonstrated that this tiny RNA is dispensable for normal development as it regulates the delicate balance between cell death and growth by repressing the p53 gene network. Furthermore, during her postdoctoral training, Dr. Le illustrated a novel mechanism of cancer crosstalk in which miRNAs secreted by metastatic breast cancer cells are delivered to non-metastatic cells via extracellular vesicles (EVs) and promote colonization of tumor cells in the lung. Recently, our group has established a new EV-based drug delivery platform with efficient and safe delivery of RNA drugs to cancer cells. With these original findings, Dr. Le’s articles have been cited over 1400 times by researchers worldwide (link). Dr. Le is also a scientific co-founder and advisor of Carmine Therapeutics, a start-up company based on red blood cell EVs, based in Singapore and Boston. Carmine Therapeutics has raised 9.5M USD seed funding and recruited about 20 employees. For more information about Dr. Le, you may visit https://lelabnus.wordpress.com/dr-le/.
more
Virtual Event Details
RUN
Time
(Friday) 4:00 pm - 5:00 pm
Organizer
Comments are closed.
